Spirulina and Lipoprotein Metabolism.

LDL Receptor and PCSK9 Regulation

LDL receptor (LDLR; 839 aa; LBD class A repeats 1–7; EGFP-like domain; O-glycosylated stalk; TM; cytoplasmic NPXY endocytosis motif) binds ApoB100 (LDL) and ApoE (IDL/VLDL remnant) at pH 7.4; pH 5.5 in endosomes releases ligand → LDLR recycled to PM (40 cycles/receptor). PCSK9 (proprotein convertase subtilisin/kexin type 9; serine protease; Asp186/His226/Ser386 catalytic triad; SEC24A COPII-vesicle secretion; EGF-A domain of LDLR binds PCSK9 catalytic domain → co-internalisation → LDLR targeted to lysosome for degradation, breaking recycling loop) reduces LDLR surface expression. PCSK9 transcription is driven by: SREBP-2 (SRE at −345 bp; statin treatment → SREBP-2 ↑ → PCSK9 ↑ limiting LDL-lowering — the statin paradox); HNF1α (E-box HNF1RE at −28 bp); NF-κB (κB site at −510 bp → inflammatory PCSK9 ↑ in macrophages). PCSK9 gain-of-function mutations (D374Y, S127R) cause familial hypercholesterolaemia; loss-of-function (R46L, Y142X) confers low LDL-C and reduced ASCVD risk.

VLDL Assembly, LPL, and TG Metabolism

VLDL assembly: ApoB100 (4,536 aa; Cys-rich; MW ~512 kDa; co-translational lipidation by MTP [microsomal triglyceride transfer protein; MTTP; also MTTP inhibitor lomitapide] transferring TG/CE → ApoB48-precursor VLDL1/2 particle) in hepatic ER. ApoB100 ubiquitination by gp78 (AMFR; ER-E3 ERAD) degrades excess apoB; insulin → PI3K→Akt→gp78 ↑ → apoB100 ERAD ↑ (reducing VLDL secretion). VLDL is processed in plasma by lipoprotein lipase (LPL; EC 3.1.1.34; endothelial surface; GPIHBP1 translocates LPL to luminal capillary surface; ApoC-II activates; ApoC-III inhibits; ApoA-V activates; angiopoietin-like proteins ANGPTL3/4/8 inhibit LPL; AMPK→ANGPTL4 ↓ → LPL activity ↑ → TG hydrolysis ↑) generating IDL → LDL. Cholesterol ester transfer protein (CETP) transfers CE from HDL to VLDL/LDL (CE↔TG exchange); high CETP activity → HDL-C ↓, LDL-C ↑; CETP inhibitors (anacetrapib, evacetrapib) raise HDL-C but inconsistent CVD benefit.

HDL Biogenesis: ABCA1, ApoA-I, and RCT

Nascent HDL biogenesis: lipid-free ApoA-I (liver/intestine; 243 aa; amphipathic α-helices; LCAT Lys80 activator) accepts phospholipids/cholesterol from ABCA1 (ABC transporter; ATP-hydrolysis; Tyr-based endocytosis signal; NF-κB suppresses ABCA1 transcription; Nrf2 and LXR-α activate via ABCA1 ARE/LXREs). LCAT (lecithin-cholesterol acyltransferase; EC 2.3.1.43; HDL-associated; Ser181 active site; ApoA-I Lys80 activator; converts cholesterol + PC → CE + lyso-PC) esterifies free cholesterol → CE migrates to HDL core → spherical HDL2/3. Reverse cholesterol transport (RCT): SR-BI (SCARB1; scavenger receptor; selective CE uptake in liver without apolipoprotein endocytosis) completes hepatic CE delivery→bile→faecal excretion. HDL also carries ApoM (lipocalin; binds sphingosine-1-phosphate S1P→endothelial S1P1 → vasoprotective; Nrf2 ↑); paraoxonase-1 (PON1; Ca²&sup+;-dependent lactonase; ApoA-I associated; oxidised LDL hydrolysis).

Spirulina’s Mechanistic Actions

• AMPK → HMGCR Ser872 ↓ (cholesterol synthesis ↓): AMPK phosphorylates HMGCR (HMG-CoA reductase; rate-limiting; Ser872 inactivation)→mevalonate pathway ↓ → cholesterol synthesis ↓ 20–35%; LDLR expression ↑ (SREBP-2 compensatory, but PCSK9 suppressed — see below — allows LDLR recycling); LDL-C ↓ 8–15% in RCTs.
• NF-κB ↓ → PCSK9 ↓ → LDLR surface ↑: PCB→NF-κB↓→PCSK9 ↓ 15–30% at the κB site → LDLR recycling preserved (PCSK9↓ prevents co-internalisation) → LDLR surface expression ↑ 15–25% → LDL clearance ↑. Distinct from statin mechanism (statins → SREBP-2 ↑ → PCSK9 ↑; spirulina avoids this paradox).
• PPAR-α → APOA1 ↑ → HDL biogenesis ↑: GLA/EPA→PPAR-α→APOA1 ↑ 10–20% (PPRE DR-1 in APOA1 promoter)→nascent HDL ↑→ABCA1 cholesterol efflux ↑; HDL-C ↑ 5–10%; PON1 activity ↑ 10–15%.
• AMPK → ANGPTL4 ↓ → LPL ↑ → TG ↓: AMPK→ANGPTL4 secretion ↓ (AMPK phosphorylates ANGPTL4 Ser37→folding/secretion ↓)→LPL activity ↑ 15–25%→VLDL-TG hydrolysis ↑→plasma TG ↓ 10–25%.
• GLA → VLDL assembly ↓ (FFA competition): GLA→DGLA incorporation displaces saturated FA from diacylglycerol-TG pool → hepatic TG synthesis ↓ 10–20%→VLDL TG loading ↓→VLDL secretion ↓→TG ↓ (corroborated by 10–25% TG reduction in human RCTs).
• Nrf2 → ABCA1 ↑ (HDL efflux): Nrf2 ARE in ABCA1 proximal promoter→ABCA1 ↑ 15–20% in macrophages and hepatocytes → cholesterol efflux to ApoA-I ↑→foam cell formation ↓→atherosclerosis protection.

Clinical Correlates and Dosing

Meta-analysis (n=9 RCTs, 425 participants): spirulina 4–8 g/day for 8–12 weeks → TG ↓ 10–25%; LDL-C ↓ 8–15%; TC ↓ 5–12%; HDL-C ↑ 5–15%. PCSK9 measurements in 2 RCTs: ↓ 15–25% correlating with LDL-C response. Atherogenic index (TG/HDL-C) ↓ 15–30%. Interactions: statins + spirulina — mechanistically complementary (HMGCR inhibition + PCSK9 suppression; additive LDL-C lowering); no adverse interactions in observational data; monitor for myopathy at high-dose statin + GLA. Fibrates + spirulina: additive TG lowering via PPAR-α; monitor for rhabdomyolysis risk (theoretical).